Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap
Eli Lilly rolled out its “Employer Connect” platform Thursday, aiming to give U.S. employers a new way to expand access to the weight-loss drug Zepbound. The Zepbound KwikPen will be available through network pharmacies for $449—same price, all doses. Shares of Lilly slipped roughly 2% in late New York trading. “By enabling coverage outside traditional benefit designs, we lower barriers to treatment,” said Kevin Hern, senior VP at Lilly. Employers are under pressure to handle surging demand for GLP-1 obesity drugs—these treatments work by mimicking gut hormones to reduce hunger and stabilize blood sugar—while also keeping benefit expenses in check. Speaking with Fierce Healthcare, Hern said the goal is to “ease tensions” that have sidelined some employers, though workers’ final